Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865579 | 0.88 | LMNA (0.40) | S1PR2S1PR1S1PR3LPAR2HTR2A | |
| SCHEMBL13232166 | 0.82 | S1PR2 (0.46) | S1PR2S1PR1S1PR3LPAR2PTGER2 | |
| SCHEMBL6207044 | 0.82 | S1PR2 (0.46) | S1PR2S1PR1S1PR3LPAR2PTGER2 | |
| SCHEMBL9121212 | 0.82 | TAAR1 (0.52) | CHRM2ADRA2BADRA2CCHRM3SLC6A4 | |
| SCHEMBL15352166 | 0.80 | FOLH1 (0.40) | S1PR2S1PR1S1PR3LPAR2CHRM2 | |
| SCHEMBL23588163 | 0.80 | AOC3 (0.50) | S1PR2S1PR1S1PR3LPAR2PTGER2 | |
| SCHEMBL14717561 | 0.80 | S1PR2 (0.48) | S1PR2S1PR1S1PR3LPAR2PTGER2 | |
| SCHEMBL5672614 | 0.80 | S1PR2 (0.44) | S1PR2S1PR1S1PR3LPAR2PTGER2 | |
| SCHEMBL4860981 | 0.80 | HIF1A (0.52) | S1PR2S1PR1S1PR3LPAR2CHRM2 | |
| SCHEMBL12420337 | 0.80 | S1PR2 (0.48) | S1PR2S1PR1S1PR3LPAR2PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352201-A1 | DYE, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL EACH COMPRISING THE DYE, AND PROCESS FOR PRODUCING DYE | FUJIFILM Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7576112-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | OLD DAVID W | 2009-06-25 | — | — | US | disclosed |
| EP-2049495-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | Allergan, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008021933-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008021933-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | S1PR2 1266/4885S1PR1 1608/4885S1PR3 1108/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | S1PR2 1266/4885S1PR1 1608/4885S1PR3 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.